| Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10269), 99-111, 2021 | 5268 | 2021 |
| Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial PM Folegatti, KJ Ewer, PK Aley, B Angus, S Becker, ... The Lancet 396 (10249), 467-478, 2020 | 2751 | 2020 |
| Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial MN Ramasamy, AM Minassian, KJ Ewer, AL Flaxman, PM Folegatti, ... The Lancet 396 (10267), 1979-1993, 2020 | 1652 | 2020 |
| Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four … M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10277), 881-891, 2021 | 1325 | 2021 |
| What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2 SH Hodgson, K Mansatta, G Mallett, V Harris, KRW Emary, AJ Pollard The lancet infectious diseases 21 (2), e26-e35, 2021 | 760 | 2021 |
| Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation KJ Ewer, GA O’Hara, CJA Duncan, KA Collins, SH Sheehy, ... Nature communications 4 (1), 2836, 2013 | 351 | 2013 |
| Preliminary assessment of the efficacy of a t-cell–based influenza vaccine, MVA-NP+ M1, in humans PJ Lillie, TK Berthoud, TJ Powell, T Lambe, C Mullarkey, AJ Spencer, ... Clinical infectious diseases 55 (1), 19-25, 2012 | 289 | 2012 |
| Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector GA O’Hara, CJA Duncan, KJ Ewer, KA Collins, SC Elias, FD Halstead, ... Journal of Infectious Diseases 205 (5), 772-781, 2012 | 252 | 2012 |
| ChAd63-MVA–vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans SH Sheehy, CJA Duncan, SC Elias, P Choudhary, S Biswas, FD Halstead, ... Molecular Therapy 20 (12), 2355-2368, 2012 | 246 | 2012 |
| Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors SH Sheehy, CJA Duncan, SC Elias, KA Collins, KJ Ewer, AJ Spencer, ... Molecular Therapy 19 (12), 2269-2276, 2011 | 204 | 2011 |
| Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors SH Sheehy, CJA Duncan, SC Elias, S Biswas, KA Collins, GA O'Hara, ... PloS one 7 (2), e31208, 2012 | 192 | 2012 |
| Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults C Ogwang, D Kimani, NJ Edwards, R Roberts, J Mwacharo, G Bowyer, ... Science translational medicine 7 (286), 286re5-286re5, 2015 | 160 | 2015 |
| Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals SH Hodgson, KJ Ewer, CM Bliss, NJ Edwards, T Rampling, ... The Journal of infectious diseases 211 (7), 1076-1086, 2015 | 155 | 2015 |
| The microbiology of chronic osteomyelitis: prevalence of resistance to common empirical anti-microbial regimens SH Sheehy, BA Atkins, P Bejon, I Byren, D Wyllie, NA Athanasou, ... Journal of infection 60 (5), 338-343, 2010 | 155 | 2010 |
| Oxford COVID Vaccine Trial Group Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in … M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... Lancet 397 (10269), 99-111, 2021 | 133 | 2021 |
| Demonstration of the Blood-Stage Plasmodium falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane … RO Payne, KH Milne, SC Elias, NJ Edwards, AD Douglas, RE Brown, ... The Journal of infectious diseases 213 (11), 1743-1751, 2016 | 112 | 2016 |
| Optimising controlled human malaria infection studies using cryopreserved P. falciparum parasites administered by needle and syringe SH Sheehy, AJ Spencer, AD Douglas, BKL Sim, RJ Longley, NJ Edwards, ... PloS one 8 (6), e65960, 2013 | 111 | 2013 |
| Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered … SH Hodgson, E Juma, A Salim, C Magiri, D Kimani, D Njenga, A Muia, ... Frontiers in microbiology 5, 686, 2014 | 108 | 2014 |
| Safety and Immunogenicity of Heterologous Prime-Boost Immunisation with Plasmodium falciparum Malaria Candidate Vaccines, ChAd63 ME-TRAP and MVA ME … C Ogwang, M Afolabi, D Kimani, YJ Jagne, SH Sheehy, CM Bliss, ... PloS one 8 (3), e57726, 2013 | 98 | 2013 |
| First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children AB Tiono, I Nébié, N Anagnostou, AS Coulibaly, G Bowyer, E Lam, ... PloS one 13 (12), e0208328, 2018 | 77 | 2018 |
